Probiotics and prevention of Clostridium difficile infection

E. J.C. Goldstein*, S. J. Johnson, P. J. Maziade, C. T. Evans, J. C. Sniffen, M. Millette, L. V. McFarland

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


The role of probiotics as adjunctive measures in the prevention of Clostridium difficile infection (CDI) has been controversial. However, a growing body of evidence has suggested that they have a role in primary prevention of CDI. Elements of this controversy are reviewed and the proposed mechanisms of action, the value and cost effectiveness of probiotics are addressed with a focus on three agents, Saccharomyces boulardii, Lactobacillus rhamnosus GG and the combination of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, Lactobacillus rhamnosus CLR2 (Bio-K+).

Original languageEnglish (US)
Pages (from-to)114-119
Number of pages6
StatePublished - Jun 2017


  • Bio-K+
  • C. difficile
  • Lactobacillus acidophilus CL1285
  • Lactobacillus casei LBC80R
  • Lactobacillus rhamnosus CLR2
  • Lactobacillus rhamnosus GG
  • Probiotic
  • Saccharomyces boulardii

ASJC Scopus subject areas

  • Microbiology
  • Infectious Diseases


Dive into the research topics of 'Probiotics and prevention of Clostridium difficile infection'. Together they form a unique fingerprint.

Cite this